Calendario›REGN›Cemiplimab

Cemiplimab

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Ensayo de REGENERON PHARMACEUTICALS, INC. en Tumores malignos avanzados.

Más ensayos de: Tumores malignos avanzados.

Fase

Fase 1

Estado

En marcha, sin reclutar

Participantes

146

previstos

Centros

20

Fin del objetivo primario

sep 2027

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en jun 2017.

Qué mide

Incidence and severity of treatment-emergent adverse events (TEAEs) in patients treated with cemiplimab as monotherapy (del registro, en inglés) (hasta 136 semanas)

Cómo lo describe el promotor

En el documentoEn inglés, del registroPart 2 Cohorts A and C This study is being conducted to test the safety and pharmacokinetics of cemiplimab in patients with lung cancer. The study is also being conducted to test if cemiplimab, alone or in combination, can reduce the size of your tumor by helping the immune system destroy the tumor. Part 2 Cohorts D and E This study is being conducted to test the safety and pharmacokinetics of fianlimab and cemiplimab in patients with lung cancer. The study is also being conducted to test if fianlimab and cemiplimab, with or without chemotherapy, can reduce the size of your tumor by helping the immune system destroy the tumor.

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03233139), actualizada en feb 2026.